Participants
Forty-two recreationally active college participants (24 male and 18 females) met the requirements to participate in this study. Key criteria for inclusion were: (a) 18–40 year of age, (b) regular recreationally training for at least 2 years with a minimum of 1 month performing resistance training, (c) free from musculoskeletal limitations, (d) agree not to ingest any other nutritional supplements or non-prescription drugs or medication that might affect the immune system or muscle growth as well as the ability to train intensely during the study, and (e) fluent in English. Key criteria used for exclusion were: (a) history of various metabolic conditions and/or diseases; (b) use of a variety of medications, including but not limited to those with androgenic and/or anabolic effects and/or nutritional supplements known to improve strength and/or muscle mass such as creatine, essential amino acid, whey protein, glutamine, dehydroepiandrosterone (DHEA) within 8 weeks prior to the beginning of the study; (d) current use of tobacco products; and/or in the case of female participants ingesting oral contraceptives; and (e) the presence of any orthopedic limitations or injuries. Compliance was confirmed verbally with participants upon arrival to the laboratory.
All participants were informed of the potential risks of the intervention before agreeing to comply with the intervention protocol and signed an informed consent. All experimental procedures were conducted in accordance with the Declaration of Helsinki, and approved by the University ethics committee. As summarized in Fig. 1, after assessing for eligibility, 27 of the 42 recruited participants completed all aspects of the study. The study was conducted during the spring and summer of 2015 at the Centre for Science and Medicine in Sport and Exercise University of Greenwich Medway Campus, Kent (UK). Trial Registration: ClinicalTrials.gov, U.S. National Institutes of Health. (Identifier: NCT02425020) on 22nd April 2015.
Experimental design
This study was a randomized controlled trial with three parallel groups, following a double blind between-participant design. Participants were randomly allocated into three treatment groups: beef protein (n = 14); whey protein (n = 14) or carbohydrate only (CHO, n = 14). Before (test 1) and after (test 2) an 8-week intervention period, measurements of performance, body composition and muscular thickness, total cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol, triglycerides, glucose, urea, uric acid, creatine kinase (CK), creatinine, alanine transaminase (AST/GOT), aspartate transaminase (ALT/GPT) and HNP1-3 salivary immune-peptides were assessed. Additionally, saliva was collected before and after the first and the last workout of the 8-week intervention protocol.
After inclusion and before the baseline assessment, participants performed six sessions of familiarization, aimed to minimize any potential learning effects of the training procedures. Following the pre-intervention assessments, participants were matched by gender and resistance training background. Assignment of participants to treatments was performed by block randomization, using a block size of three, and in a double-blind fashion. Initial groups characteristics were as follows: beef: age 25.6 ± 5.7 years, height 1.72 ± 0.09 m, body mass 74.2 ± 17.3 kg; whey: age 25.9 ± 5.9 years, height 1.71 ± 0.10 m, body mass 70.2 ± 11.3 kg; CHO: age 24.9 ± 8.1 years, height 1.70 ± 0.09 m, body mass 70.4 ± 15.3 kg. No significant differences were observed between treatments at inclusion in sample characteristics.
Dietary supplementation
The three products under study were presented as 20 g sachets of vanilla-flavored powder to be diluted in 250 mL of cold orange juice at each intake. The diluted drinks were similar in appearance, texture and taste and were isoenergetic. The nutritional composition of each product and the amino acids profile of beef and whey proteins are shown in Table 1. Products were taken once a day for 8 weeks (56 total doses per participant). On training days (resistance training or recreational exercise sessions), the supplement was ingested just after training, whereas on non-training days, the product was administered in the morning, before having breakfast.
Table 1 Nutritional composition of drinks per intake (20 g of powder plus 250 mL of orange juice)
Dietary (nutrition) monitoring
A research nutritionist collected dietary habits and explained the proper procedures for recording dietary intake. Each participant completed a 3-day food diary report (2 weekdays, and 1 weekend day). The food diary report was then analyzed using Dietplan 6 software to determine energy and macronutrient content. Participants were instructed to maintain their normal diet throughout the training period. To determine changes and evaluate differences caused by the supplementation protocol, diet composition was analyzed again during the last week of the intervention protocol.
Measurements
Body composition
Body mass (BM) and height were assessed, on a standard scale and stadiometer according the methods described by Ross and Marfel-Jones (1991).
Whole body densitometry was assessed using air displacement via the Bod Pod® (Life Measurements, Concord, CA, USA) in accordance with the manufacturer’s instructions as detailed elsewhere (Dempster and Aitkens 1995). Briefly, the participants were tested wearing only tight fitting clothing (swimsuit or undergarments) and an acrylic swim cap. Volunteers wore exactly the same clothing for all testing. Thoracic gas volume was estimated for all participants using a predictive equation integral to the Bod Pod® software. The calculated value for body density was used in the Siri equation (Siri 1961) to estimate the body composition. A complete body composition measurement was performed twice. If the agreement on percentage of body fat was within 0.05%, the two tests were averaged. If the two tests were not within the 0.05% agreement, a third test was performed and, then, the average of the three completed trials was used for all body composition variables.
Muscular thickness
Right-side vastus medialis muscle thicknesses were measured in real time using an Diasus diagnostic ultrasound imaging unit (Dynamic Imaging, Livingston, Scotland UK) coupled to a 50 mm probe at a frequency of 7.5 MHZ while participants were lying supine with arms and legs completely relaxed. The right lower limb was positioned with the knee extended. The probe was placed perpendicular to the skin surface and bone tissues at 80% of the distance between the lateral condyle of the femur and greater trochanter (Bradley and O’Donnell 2002). The probe was coated with a water-soluble transmission gel (Aquasonic 100 Ultrasound Transmission gel) to provide acoustic contact without depressing the dermal surface. Thickness was calculated as the distance between superficial and deep aponeuroses measured at the ends and middle region of each 3.8 cm-wide sonograph.
Three images of each muscle were obtained for each point and the average of the results was calculated. To favor reproducibility, probe placement was carefully noted for reproduction during the other test sessions and the same operator performed all the measurements. To avoid any swelling in the muscles that could disturb the results, images were obtained at least 48 h before and after the program intervention.
Training, performance evaluation and control of the intervention compliance
All participants followed the same resistance training routine, three times per week alternated with their habitual recreational recreationally training (games or team sport oriented activity) for a total of 8 weeks (24 resistance training workouts). During the 8 weeks of intervention, participants carried out their workout session late in the afternoon or early evening. After a warm up, the participants performed a total of three circuits involving one set of the following 8 resistance exercises: (1) jump-squat (2) bench press, (3) parallel back squat, (4) upright row, (5) dumbbell alternate lunges, (6) shoulder press, (7) lateral hurdle jumps, and (8) abdominal crunch.
Every exercise included 12 maximum repetitions using the heaviest possible load (except the abdominal crunch that involved 20 repetitions per sets). A minimum rest was permitted in between exercises (only the time required to change from one exercise to the following). Recovery between circuits was 2–3 min. Resistance training sessions were completed in about 30 min. All training sessions were closely monitored to ensure effort, repetitions and intensity established by experienced strength and conditioning coaches. All participants completed all lifts for each exercise. The total load (kg) summarized all repetitions from the first six exercises was considered as the indicator of performance. Although lateral hurdle jumps and abdominals were performed with no external load, performing these exercises at the end of every circuit would impact on general fitness adaptation and the accumulated level of fatigue over the training session. The first and last workouts of the intervention period were used as evaluation sessions. The participants were instructed to refrain from any vigorous activity for 48 h and avoid caffeine ingestion for at least 48 h prior to both assessment sessions. As occurred during the entire training period, the first and last sessions were performed at the same time of the day for the same participant. After completing the first session, each participant was given a batch of products, according to randomization.
Tolerance, collected from adverse events and compliance with product intake (determined by an individual follow up of the participants), was evaluated continuously during the intervention. Only the participants who completed all the 24 training sessions were included in the final analysis.
Blood indices of health
Blood chemistry samples were taken before and after the 8-week intervention period. Participants arrived at the physiology laboratory, after a fasting period of 6–8 h, on two separate occasions (1 day before and 1–2 days after completing the 8-week intervention period). Finger-prick capillary whole blood specimens were collected from each subject, under resting conditions, and analyzed using the Cholestech LDX Analyzer for fasting total cholesterol, HDL, LDL cholesterol triglycerides, and glucose, or the Reflotron Plus Clinical Chemistry Analyzer for CK, creatinine, AST/GOT, ALT/GPT, urea and uric acid. Both devices were used according to the manufacturer’s instructions, using test strips (Reflotron Plus Clinical Chemistry Analyzer) or cassette (Cholestech LDX Analyzer).
Salivary alpha-defensins HNP1-3
Saliva collection
Saliva was collected at pre (before and after the first workout) and post (before and after the last workout) 8-week intervention period. At baseline or pre-workout, saliva samples were collected following the blood samples just a few minutes before starting the workout. For the post-workout sample, saliva was collected within 5 min after the exercise cessation.
Participants remained seated, performing minimal movement for 10 min (pre-workout) or 5 min (post-workout) prior to each saliva collection. For all saliva samples, the mouth was rinsed with water at least 5 min before the collection. The participant was requested to swallow to empty the mouth before each sample collection. Unstimulated whole saliva was collected by the spitting method while the participant remained seated, leaning forward and with the heads tilted down (Navazesh 1993). Saliva was collected for 1 min. To avoid circadian variation, saliva samples were collected in between 2 and 7 pm. The collected saliva was weighed to obtain precise flow rate (g/min) (Dawidson et al. 1996). The saliva was stored at −80 °C until further sample treatment and analysis.
Saliva analysis
Saliva samples were centrifuged (12,000g, 10 min; 4 °C) and the supernatant diluted 1000× with sample dilution buffer. Each sample was analyzed in duplicate with ELISA (Hycult biotech, The Netherlands) following the manufactures instructions. The calibration curve consisted of eight standards, ranging from 0.15 to 10 μg/mL HNP1-3. Absorbance (450 nm) values for the saliva samples were interpolated from calibration standards with a 4-parameter logistic curve (My assays, version 2015). In addition, the alpha-defensins HNP1-3 secretion rates were determined by multiplying their concentration by the flow rate (mL min−1).
Statistical analysis
Sensitivity of the final sample size was calculated assuming a model with three groups and four repeated measures, 0.05 α error probability, and 0.80 power (1 − β), to ensure adequacy of the study. A descriptive analysis was performed and subsequently the Kolmogorov–Smirnov and Shapiro–Wilk test were applied to assess normality. Sample characteristics at baseline were compared between conditions (beef vs. whey vs. CHO) using one-way analysis of variance (ANOVA). Change from pre to post in performance, body composition, muscle thickness, and blood indices was calculated by subtracting pre- from post-values. Differences in change between conditions were assessed using one-way ANOVA. The changes in the concentration and secretion of HNP1-3 or the saliva flow rates were additionally analyzed using three conditions (beef vs. whey vs. CHO) × four times (pre-workout 1st vs. post-workout 1st vs. pre-workout 24th vs. post-workout 24th) repeated measures ANCOVA, using pre-workout 1st as covariate. Bonferroni-adjusted post hoc analyses were performed when appropriate. Generalized eta squared (\( \eta_{\text{G}}^{2} \)) and Cohen’s d values were reported to provide an estimate of standardized effect size (small d = 0.2, \( \eta_{\text{G}}^{2} \) = 0.01; moderate d = 0.5, \( \eta_{\text{G}}^{2} \) = 0.06; and large d = 0.8, \( \eta_{\text{G}}^{2} \) = 0.14). Significance level was set to p < 0.05. Results are reported as mean ± SD unless stated otherwise. Data analyses were performed with Stata 13.1 (StataCorp, College Station, TX, USA).